Dr. Iris Marin Collazo, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 166
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME117021
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 166
- Services billed
- 9,221
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 81 | 70 |
| Established patient office or other outpatient visit, 40-54 minutes | 52 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 21 | 21 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Duloxetine Hcl Other prescribers in Jacksonville, FL | 29 |
| Gabapentin Other prescribers in Jacksonville, FL | 27 |
| Cyclobenzaprine Hcl Other prescribers in Jacksonville, FL | 23 |
| Baclofen Other prescribers in Jacksonville, FL | 21 |
| Oxcarbazepine Other prescribers in Jacksonville, FL | 16 |
| Tecfidera (dimethyl fumarate) | 12 |
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in Jacksonville, FL | 12 |
| Topiramate Other prescribers in Jacksonville, FL | 12 |
| Amitriptyline Hcl Other prescribers in Jacksonville, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 16 payments worth $3,015 in total to this clinician.
| Tg Therapeutics, Inc. | $1,242 |
|---|---|
| Genentech USA, Inc. | $825 |
| Biogen, Inc. | $236 |
| Ambu Inc. | $234 |
| Amgen Inc. | $199 |
| Genentech, Inc. | $126 |
| Novartis Pharmaceuticals Corporation | $121 |
| Genzyme Corporation | $32.25 |
| Consulting Fee | $1,988 |
|---|---|
| Food and Beverage | $1,027 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tg Therapeutics, Inc. Jul 21, 2025 | Consulting Fee BRIUMVI · Immunology | $1,013 |
| Genentech USA, Inc. Dec 9, 2025 | Consulting Fee | $825 |
| Biogen, Inc. May 14, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $59,057 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.